Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of efficacy and safety of add-on therapy with the synthetic cannabinomimetic nabilone in patients with cancer pain
2009-011862-27Phase 3Terminated
- Sponsor
- ZISOP Zentrum für interdisziplinäre Schmerztherapie
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nabilone in cancer pain and Nonhematologic neoplasms, sponsored by ZISOP Zentrum für interdisziplinäre Schmerztherapie. Primary endpoint: Intensity of pain (VAS). Started Aug 2009; status: terminated.
02
Drugs
nabilone
03
Conditions
cancer painNonhematologic neoplasms
Beyond the preview
Go deeper on 2009-011862-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011862-27.